These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

717 related articles for article (PubMed ID: 15183900)

  • 21. [ABO blood groups and platelet transfusion].
    Eckstein R; Zeiler T; Zingsem J; Heuft HG; Musch R; Weisbach V
    Beitr Infusionsther; 1990; 26():157-9. PubMed ID: 1703819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Platelet transfusion: products, indications, dose, threshold and efficacy].
    Andreu G; Vasse J; Tardivel R; Semana G
    Transfus Clin Biol; 2009 May; 16(2):118-33. PubMed ID: 19443257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design.
    Tinmouth A; Tannock IF; Crump M; Tomlinson G; Brandwein J; Minden M; Sutton D
    Transfusion; 2004 Dec; 44(12):1711-9. PubMed ID: 15584985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The transfusion of HLA-matched platelets to thrombocytopenic patients resistant to random donor platelets.
    Levy L; Woodfield DG
    N Z Med J; 1984 Oct; 97(766):719-21. PubMed ID: 6595558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet transfusion therapy.
    AuBuchon JP
    Clin Lab Med; 1996 Dec; 16(4):797-816. PubMed ID: 8974196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current practice and future directions for optimization of platelet transfusions in patients with severe therapy-induced cytopenia.
    Apelseth TO; Hervig T; Bruserud O
    Blood Rev; 2011 May; 25(3):113-22. PubMed ID: 21316823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of patients refractory to platelet transfusion.
    Chockalingam P; Sacher RA
    J Infus Nurs; 2007; 30(4):220-5. PubMed ID: 17667077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.
    Kerkhoffs JL; van Putten WL; Novotny VM; Te Boekhorst PA; Schipperus MR; Zwaginga JJ; van Pampus LC; de Greef GE; Luten M; Huijgens PC; Brand A; van Rhenen DJ;
    Br J Haematol; 2010 Jul; 150(2):209-17. PubMed ID: 20507310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation.
    Wandt H; Schaefer-Eckart K; Frank M; Birkmann J; Wilhelm M
    Bone Marrow Transplant; 2006 Feb; 37(4):387-92. PubMed ID: 16400342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet transfusion refractoriness.
    Hod E; Schwartz J
    Br J Haematol; 2008 Jul; 142(3):348-60. PubMed ID: 18510692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lower or higher doses for prophylactic platelet transfusions: results of a meta-analysis of randomized controlled trials.
    Cid J; Lozano M
    Transfusion; 2007 Mar; 47(3):464-70. PubMed ID: 17319827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients.
    Heal JM; Blumberg N; Masel D
    Blood; 1987 Jul; 70(1):23-30. PubMed ID: 3474041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of platelet transfusion triggers in a tertiary-care hospital.
    Cameron B; Rock G; Olberg B; Neurath D
    Transfusion; 2007 Feb; 47(2):206-11. PubMed ID: 17302765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands.
    Postma MJ; van Hulst M; De Wolf JT; Botteman M; Staginnus U
    Transfus Med; 2005 Oct; 15(5):379-87. PubMed ID: 16202052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An audit of platelet transfusion within the Wellington Cancer Centre.
    Buhrkuhl DC; Karlsson MK; Carter JM
    Intern Med J; 2012 Jan; 42(1):65-70. PubMed ID: 21040321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The current status of platelet and granulocyte transfusions.
    Seidl S; Kilp M
    Haematologia (Budap); 1980; 13(1-4):145-54. PubMed ID: 7019021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Compliance with prophylactic platelet transfusion trigger in haematological patients.
    Eikenboom JC; van Wordragen R; Brand A
    Transfus Med; 2005 Feb; 15(1):45-8. PubMed ID: 15713128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Posttransfusion platelet count increments after ABO-compatible versus ABO-incompatible platelet transfusions in noncancer patients: an observational study.
    Pavenski K; Warkentin TE; Shen H; Liu Y; Heddle NM
    Transfusion; 2010 Jul; 50(7):1552-60. PubMed ID: 20210928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.
    Janetzko K; Cazenave JP; Klüter H; Kientz D; Michel M; Beris P; Lioure B; Hastka J; Marblie S; Mayaudon V; Lin L; Lin JS; Conlan MG; Flament J
    Transfusion; 2005 Sep; 45(9):1443-52. PubMed ID: 16131376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of patients with hematologic malignancies and aplastic anemia who are refractory to platelet transfusions.
    Sandler SG
    Haematologia (Budap); 1998; 29(1):1-11. PubMed ID: 9704252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.